Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Disruption of the blood–brain barrier (BBB) is a hallmark of acute inflammatory lesions in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis. This disruption may precede and facilitate the infiltration of encephalitogenic T cells. The signaling events that lead to this BBB disruption are incompletely understood but appear to involve dysregulation of tight-junction proteins such as claudins. Pharmacological interventions aiming at stabilizing the BBB in MS might have therapeutic potential. Here, we show that the orally available small molecule LY-317615, a synthetic bisindolylmaleimide and inhibitor of protein kinase Cβ, which is clinically under investigation for the treatment of cancer, suppresses the transmigration of activated T cells through an inflamed endothelial cell barrier, where it leads to the induction of the tight-junction molecules zona occludens-1, claudin 3, and claudin 5 and other pathways critically involved in transendothelial leukocyte migration. Treatment of mice with ongoing experimental autoimmune encephalomyelitis with LY-317615 ameliorates inflammation, demyelination, axonal damage, and clinical symptoms. Although LY-317615 dose-dependently suppresses T-cell proliferation and cytokine production independent of antigen specificity, its therapeutic effect is abrogated in a mouse model requiring pertussis toxin. This abrogation indicates that the anti-inflammatory and clinical efficacy is mainly mediated by stabilization of the BBB, thus suppressing the transmigration of encephalitogenic T cells. Collectively, our data suggest the involvement of endothelial protein kinase Cβ in stabilizing the BBB in autoimmune neuroinflammation and imply a therapeutic potential of BBB-targeting agents such as LY-317615 as therapeutic approaches for MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complex Phenotype of Mice Lacking Occludin, a Component of Tight Junction Strands
Saitou, M., Furuse, M., Sasaki, H., Schulzke, J.-D., Fromm, M., Takano, H., Noda, T., & Tsukita, S. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4131 · Cited by 1,195 · cited 1×
“Claudin 5 is highly expressed in brain endothelial cells (9) and necessary to ensure BBB integrity (39, 40).”
BackgroundWnt/β-catenin signaling controls development of the blood–brain barrier
Liebner, S., Corada, M., Bangsow, T., Babbage, J., Taddei, A., Czupalla, C. J., Reis, M., Felici, A., Wolburg, H., Fruttiger, M., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806024 · Cited by 860
The Hedgehog Pathway Promotes Blood-Brain Barrier Integrity and CNS Immune Quiescence
Alvarez, J. I., Dodelet-Devillers, A., Kebir, H., Ifergan, I., Fabre, P. J., Terouz, S., Sabbagh, M., Wosik, K., Bourbonnière, L., Bernard, M., et al. (2011) · Science · doi:10.1126/science.1206936 · Cited by 845
Wnt/β-catenin signaling is required for CNS, but not non-CNS, angiogenesis
Daneman, R., Agalliu, D., Zhou, L., Kuhnert, F., Kuo, C. J., & Barres, B. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805165106 · Cited by 753
VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown
Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A., & John, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808698106 · Cited by 666
Cellular mechanisms of IL-17-induced blood-brain barrier disruption
Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., Bechmann, I., Becher, B., Luhmann, H. J., Waisman, A., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-141978 · Cited by 529 · cited 1×
“Although mediators from infiltrating T cells such as the T helper cytokine interleukin17 (IL-17) are certainly capable of sustaining BBB disruption in inflammatory lesions (38), the question whether BBB disruption precedes infiltration of pathogenic T cells and which factors are responsible for this disruption remains…”
BackgroundDisruption of central nervous system barriers in multiple sclerosis
Alvarez, J. I., Cayrol, R., & Prat, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.017 · Cited by 334 · cited 1×
“In autoimmune inflammatory diseases of the CNS such as multiple sclerosis (MS), which is characterized by perivascular infiltrates of autoreactive, encephalitogenic T cells and subsequent demyelination and neuronal loss, BBB disruption is a hallmark of acute inflammatory lesions (3).”
BackgroundEvolution of the blood–brain barrier in newly forming multiple sclerosis lesions
Gaitán, M. I., Shea, C. D., Evangelou, I. E., Stone, R. D., Fenton, K. M., Bielekova, B., Massacesi, L., & Reich, D. S. (2011) · Annals of Neurology · doi:10.1002/ana.22472 · Cited by 174 · cited 1×
“Although the question whether BBB disruption is a primary or secondary event in lesion evolution is still a matter of debate, there is increasing evidence from studies of human MS plaques (4) and animal models of MS, such as experimental autoimmune encephalomyelitis (EAE), that the BBB integrity is disturbed as an ear…”
ResultPfeiffer, F., Schäfer, J., Lyck, R., Makrides, V., Brunner, S., Schaeren-Wiemers, N., Deutsch, U., & Engelhardt, B. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0883-2 · Cited by 160 · cited 2×
“Conversely, induced expression of claudin 1 in cerebral endothelial cells ameliorates EAE (10).”
BackgroundWeidenfeller, C., Schrot, S., Zozulya, A., & Galla, H.-J. (2005) · Brain Research · doi:10.1016/j.brainres.2005.06.049 · Cited by 112
Cited by
Claudin-5: gatekeeper of neurological function
Greene, C., Hanley, N., & Campbell, M. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0123-z · Cited by 583
Barrier function in the peripheral and central nervous system—a review
Reinhold, A., & Rittner, H. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1920-8 · Cited by 275
Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
White-matter free-water diffusion MRI in schizophrenia: A systematic review and meta-analysis
Carreira Figueiredo, I., Borgan, F., Pasternak, O., Turkheimer, F. E., & Howes, O. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01272-x · Cited by 65
“When disrupted, abnormal trafficking of cells and molecules between the peripheral blood and the brain occur, allowing bone marrow-derived immune cells to cross into the nervous system [46], and increasing the extracellular fractional volume [47].”
Blood brain barrier inflammation and potential therapeutic role of phytochemicals
Welcome, M. O. (2020) · PharmaNutrition · doi:10.1016/j.phanu.2020.100177 · Cited by 22
Metadata
- Authors
- Lanz, T. V., Becker, S., Osswald, M., Bittner, S., Schuhmann, M. K., Opitz, C. A., Gaikwad, S., Wiestler, B., Litzenburger, U. M., Sahm, F., Ott, M., Iwantscheff, S., Grabitz, C., Mittelbronn, M., von Deimling, A., Winkler, F., Meuth, S. G., Wick, W., & Platten, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-08-19
- Volume
- 110
- Issue
- 36
- Pages
- 14735-14740
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2107514209
- Cited by
- 56
- References
- 10
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis. https://app.cochat.ai/papers/10.1073/pnas.1302569110
- The paper
- Lanz, T. V., Becker, S., Osswald, M., Bittner, S., Schuhmann, M. K., Opitz, C. A., Gaikwad, S., Wiestler, B., Litzenburger, U. M., Sahm, F., Ott, M., Iwantscheff, S., Grabitz, C., Mittelbronn, M., von Deimling, A., Winkler, F., Meuth, S. G., Wick, W., & Platten, M. (2013). Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1302569110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.